Presence of Differentiating Neuroblasts in Bone Marrow is a Favorable Prognostic Factor for Bone Marrow Metastatic Neuroblastoma at Diagnosis
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: The prognostic impact of the presence of differentiating neuroblasts in bone marrow (BM) remains unclear in BM metastatic neuroblastoma (NB). We aimed to identify the prognostic impact of differentiating neuroblasts in BM at diagnosis and after chemotherapy. Methods: A total of 51 patients diagnosed with BM metastatic NB at Asan Medical Center between January 1990 and July 2005 were enrolled. BM histology and laboratory data along with overall survival (OS) were compared with regard to the differentiation status of neuroblasts in BM at diagnosis and after chemotherapy. Results: Among the 51 patients, 13 (25.5%) exhibited differentiating neuroblasts in BM at diagnosis and 17/51 (33.3%) exhibited them after chemotherapy. The only significant difference among patient groups was the improved OS in patients with differentiated neuroblasts in BM at diagnosis (P =0.021). In contrast, the differentiation status of neuroblasts in BM after chemotherapy did not affect OS (P =0.852). Conclusions: Our study is the first report describing the presence of differentiating neuroblasts in BM. The presence of differentiating neuroblasts in BM at diagnosis may be a favorable prognostic factor for patients with BM metastatic NB; however, the same phenomenon after chemotherapy is irrelevant to prognosis.
Abstract
Background: The prognostic impact of the presence of differentiating neuroblasts in bone marrow (BM) remains unclear in BM metastatic neuroblastoma (NB). We aimed to identify the prognostic impact of differentiating neuroblasts in BM at diagnosis and after chemotherapy. Methods: A total of 51 patients diagnosed with BM metastatic NB at Asan Medical Center between January 1990 and July 2005 were enrolled. BM histology and laboratory data along with overall survival (OS) were compared with regard to the differentiation status of neuroblasts in BM at diagnosis and after chemotherapy. Results: Among the 51 patients, 13 (25.5%) exhibited differentiating neuroblasts in BM at diagnosis and 17/51 (33.3%) exhibited them after chemotherapy. The only significant difference among patient groups was the improved OS in patients with differentiated neuroblasts in BM at diagnosis (P =0.021). In contrast, the differentiation status of neuroblasts in BM after chemotherapy did not affect OS (P =0.852). Conclusions: Our study is the first report describing the presence of differentiating neuroblasts in BM. The presence of differentiating neuroblasts in BM at diagnosis may be a favorable prognostic factor for patients with BM metastatic NB; however, the same phenomenon after chemotherapy is irrelevant to prognosis.
참고문헌 (20)
- Shimada H, "Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee", Cancer, 86, pp.349~363 (1999)
- Peuchmaur M, "Revision of the International Neuroblastoma Pathology Classification: confirmation of favorable and unfavorable prognostic subsets in ganglioneuroblastoma, nodular", Cancer, 98, pp.2274~2281 (2003)
- Howman-Giles R, "Neuroblastoma and other neuroendocrine tumors", Semin Nucl Med, 37, pp.286~302 (2007)
- Brodeur GM, "International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma", J Clin Oncol, 6, pp.1874~1881 (1988)
- Maris JM, "Neuroblastoma", Lancet, 369, pp.2106~2120 (2007)
- Haas D, "Complete pathologic maturation and regression of stage IVS neuroblastoma without treatment", Cancer, 62, pp.818~825 (1988)
- Iwanaka T, "Maturation of mass-screened localized adrenal neuroblastoma", J Pediatr Surg, 36, pp.1633~1636 (2001)
- McLaughlin JE, "Maturing neuroblastoma and ganglioneuroblastoma: a study of four cases with long survival", J Pathol, 121, pp.19~26 (1977)
- Rozmus J, "Multiple persistent ganglioneuromas likely arising from the spontaneous maturation of metastatic neuroblastoma", J Pediatr Hematol Oncol, 34, pp.151~153 (2012)
- Eklof O, "Spontaneous regression of stage IV neuroblastoma", Acta Paediatr Scand, 72, pp.473~476 (1983)
- Lonergan GJ, "Neuroblastoma, ganglioneuroblastoma, and ganglioneuroma: radiologic-pathologic correlation", Radiographics, 22, pp.911~934 (2002)
- Schmidt ML, "Biologic factors determine prognosis in infants with stage IV neuroblastoma: A prospective Children’s Cancer Group study", J Clin Oncol, 18, pp.1260~1268 (2000)
- Bagatell R, "Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidy", J Clin Oncol, 23, pp.8819~8827 (2005)
- Tornóczky T, "Pathology of peripheral neuroblastic tumors: significance of prominent nucleoli in undifferentiated", poorly differentiated neuroblastoma, 2007, pp.13, 269~275
- Ogita S, "Neuroblastoma: incomplete differentiation on the way to maturation or morphological alteration resembling maturity?", Oncology, 45, pp.148~152 (1988)
- metaiodobenzylguanidine in chemoresistant neuroblastoma, "Med Pediatr Oncol", 1999, 418~419
- Reynolds CP, "Retinoid therapy of high-risk neuroblastoma", Cancer Lett, 197, pp.185~192 (2003)
- Calvo W, "Schwann cells of the bone marrow", Blood, 36, pp.180~188 (1970)
- Nakagawara A, "Dopaminergic neuroblastoma as a poor prognostic subgroup", J Pediatr Surg, 23, pp.346~349 (1988)
- Candito M, "Methylated catecholamine metabolites for diagnosis of neuroblastoma", Med Pediatr Oncol, 20, pp.215~220 (1992)